Brian T Hill

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Brian T Hill
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio Electronic address
    Biol Blood Marrow Transplant 22:1588-95. 2016
  2. doi request reprint Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration
    Brian T Hill
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 53:589-95. 2012
  3. doi request reprint Acute myeloid leukemia: when to transplant in first complete remission
    Brian T Hill
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Hematol Malig Rep 5:101-8. 2010
  4. doi request reprint Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:1738-46. 2010
  5. doi request reprint The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Br J Haematol 152:561-9. 2011
  6. doi request reprint Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 52:986-93. 2011
  7. doi request reprint Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Sanghee Hong
    Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio
    Biol Blood Marrow Transplant 22:1141-4. 2016
  8. doi request reprint Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation
    Betty K Hamilton
    Blood and Marrow Transplant Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Am J Hematol 90:144-8. 2015
  9. doi request reprint Is rituximab sub-optimally dosed in indolent B cell lymphoma?
    Yazeed Sawalha
    Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA
    Br J Haematol 174:721-9. 2016
  10. doi request reprint Comparative Effectiveness of Busulfan and Fludarabine Versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for AML/MDS
    Moaath Mustafa Ali
    Internal Medicine, Cleveland Clinic, Cleveland, OH
    Biol Blood Marrow Transplant . 2017

Collaborators

  • Brian J Bolwell
  • Brad Pohlman
  • Robert M Dean
  • Edward A Copelan
  • M E Kalaycio
  • Stephen D Smith
  • Betty K Hamilton
  • Navneet S Majhail
  • Ronald Sobecks
  • Moaath Mustafa Ali
  • Aaron T Gerds
  • Yazeed Sawalha
  • Rabi Hanna
  • Deepa Jagadeesh
  • Sanghee Hong
  • Donna Abounader
  • Lisa Rybicki
  • Jamie Starn
  • Victoria Winslow
  • Hien Liu
  • Lisa A Rybicki
  • Steven Andresen
  • Christina Ferraro
  • Melissa A Yurch
  • Donna M Abounader
  • Hien D Liu
  • Mitchell R Smith
  • Basel Rouphail
  • Xuefei Jia
  • Hien Duong
  • Housam Haddad

Detail Information

Publications10

  1. doi request reprint Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Brian T Hill
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio Electronic address
    Biol Blood Marrow Transplant 22:1588-95. 2016
    ..Consistent with previous reports, there is a significant range of Bu AUC levels, with a standard deviation of 13%. These data provide rationale for our prospective clinical trial of real-time therapeutic dose monitoring of Bu. ..
  2. doi request reprint Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration
    Brian T Hill
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 53:589-95. 2012
    ..Moreover, LPI by CLL is not a bystander effect secondary to acute inflammation, but instead represents a distinct pathologic process in a subset of patients...
  3. doi request reprint Acute myeloid leukemia: when to transplant in first complete remission
    Brian T Hill
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Hematol Malig Rep 5:101-8. 2010
    ..Because of the expanded use of umbilical cord blood as a source of hematopoietic stem cells and the use of reduced-intensity conditioning regimens, allogeneic HSCT is an option for an increasing number of patients with AML...
  4. doi request reprint Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:1738-46. 2010
    ..NMA second transplants were associated with substantially less NRM and despite a higher incidence of relapse, significantly improved survival compared to MA second transplants...
  5. doi request reprint The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Br J Haematol 152:561-9. 2011
    ..After ASCT, surviving patients have significantly increased risk mortality rates relative to the general population and this excess risk persists over time...
  6. doi request reprint Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 52:986-93. 2011
    ..001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD...
  7. doi request reprint Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Sanghee Hong
    Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio
    Biol Blood Marrow Transplant 22:1141-4. 2016
    ..Similarly, SES was not associated with survival in a subset analysis of 303 patients who had survived for 1 year after transplantation. ..
  8. doi request reprint Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation
    Betty K Hamilton
    Blood and Marrow Transplant Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Am J Hematol 90:144-8. 2015
    ..However, there may be an increased risk of severe GVHD with MMF+CSA compared to MTX+CSA. Further studies evaluating optimal dosing strategies are needed...
  9. doi request reprint Is rituximab sub-optimally dosed in indolent B cell lymphoma?
    Yazeed Sawalha
    Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA
    Br J Haematol 174:721-9. 2016
    ..In conclusion, under current practices, a subset of patients with iNHL, i.e., FL treated with R-CTX, may be sub-optimally dosed with rituximab. ..
  10. doi request reprint Comparative Effectiveness of Busulfan and Fludarabine Versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for AML/MDS
    Moaath Mustafa Ali
    Internal Medicine, Cleveland Clinic, Cleveland, OH
    Biol Blood Marrow Transplant . 2017
    ..Future prospective investigation comparing these regimens with larger patient cohorts, additional strategies to prevent relapse and limit toxicities as well as cost-effectiveness analyses are warranted...